Livedo reticularis from amantadine

SKINmed

Volumn 9, Issue 5, 2011, Pages 320-321

  Xu, Lisa Y ^a   Liu, Austin ^b   Kerr, Holly A ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT;

AGED; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; HUMAN; LIVEDO RETICULARIS; MALE; PARKINSON DISEASE; PATHOLOGY; TIME;

AGED; AMANTADINE; ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIVEDO RETICULARIS; MALE; PARKINSON DISEASE; TIME FACTORS;

EID: 84855175634     PISSN: 15409740     EISSN: 17517125     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Singer C, Papapetropoulos S, Gonzalez MA, et al. Rimantadine in Parkinson’s disease patients experiencing peripheral adverse effects from amantadine: report of a case series. Mov Disord. 2005;20:873–877.
2. Vollum DI, Parkes JD, Doyle D. Livedo reticularis during amantadine treatment. Br Med J. 1971;2:627–628.
3. Minutilli E, Pompili M, Pelecca G, Rapaccini GL, et al. Amantadineinduced livedo reticularis occurring during treatment of chronic hepatitis C. J Eur Acad Dermatol Venereol. 2008;22:1368–1370.
4. Kraemer M, Linden D, Berlit P. The spectrum of differential diagnosis in neurological patients with livedo reticularis and livedo racemosa. A literature review. J Neurol. 2005;252:1155–1166.
5. Paulson GW, Brandt JT. Amantadine, livedo reticularis, and antiphospholipid antibodies. Clin Neuropharmacol. 1995;18: 466–467.
6. Hayes BB, Cook-Norris RH, Miller JL, et al. Amantadine-induced livedo reticularis: a report of two cases. J Drugs Dermatol. 2006;5:288–289.
7. Sladden MJ, Nicolaou N, Johnston GA, et al. Livedo reticularis induced by amantadine. Br J Dermatol. 2003;149:656–658.